Therefore, anti-TIM-3 antibodies, mainly in combination with anti-PD-1/PD-L1 immune checkpoint inhibition, are currently being evaluated in clinical trials for the treatment of advanced cancers, including CRC [10,33]. The gene discussed is HAVCR2; the disease is cancer.